Premium
P4–248: Neuroparin (C3), an orally administered low molecular weight glycosaminoglycan, improves behavior and ameliorates amyloid–beta pathology in a double transgenic mouse model of Alzheimer's disease (APPSwe, PSEN1dE9)
Author(s) -
Lee John M.,
Cook Casey N.,
Hejna Matthew J.,
McGuire Susan O.
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.1987
Subject(s) - heparan sulfate , glycosaminoglycan , senile plaques , chemistry , genetically modified mouse , amyloid beta , transgene , proteoglycan , endocrinology , alzheimer's disease , medicine , amyloid precursor protein , gliosis , pathology , biochemistry , extracellular matrix , disease , gene , peptide
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom